Adsilico
Adsilico has developed a method for trialling new devices before entering human clinical tests that the company claims reduces costs, accelerates R&D timelines and eliminates the need for animal testing.
Adsilico has raised €16M across 2 funding rounds from 4 investors, most recently a Series A round in Oct 2026. Based in Leeds, UK; active in Healthtech. Data as of 28 Oct 2026.
Leeds, UKadsilico.uk ↗
Total raised
€16M
€16,024,134
Funding rounds
2
Investors
4
distinct backers
Active since
2024-02
latest 2026-10
Funding by year
EUR raised per year · 2026 YTDAdsilico — funding by year — interactive chart.
Data table
| Adsilico — funding by year | |
|---|---|
| 2024 | €4.1M |
| 2026 | €12M |
Signals
High confidenceRaise-next likelihood16
base rate 44% for Series A
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood15
base rate 11% (2+ rounds)
- ▼ Young (<3y)
- ▲ Recently backed by strong-exit-track investors
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-26 | Series A | €12M | Northern Gritstone,Parkwalk Advisors,PXN Ventures | View deal → |
| 2024-02-26 | Other | €4.1M | Northern Gritstone,Parkwalk Advisors | View deal → |